Progyny (NASDAQ:PGNY) Stock: Insider Melissa Cummings Sells 1,879 Shares

Posted by Brian Himes on Oct 18th, 2026

Progyny, Inc. (NASDAQ:PGNY – Get Free Report) COO Melissa Cummings sold 1,879 shares of the firm’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total transaction of $52,612.00. Following the sale, the chief operating officer owned 66,496 shares in the company, valued at approximately $1,861,888. This represents a 2.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Stock Performance

PGNY opened at $26.86 on Friday. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $33.06. The company has a fifty day moving average of $26.40 and a two-hundred day moving average of $25.46. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of 29.20, a PEG ratio of 1.85 and a beta of 1.02.

Progyny (NASDAQ:PGNY – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The business had revenue of $350.51 million during the quarter, compared to the consensus estimate of $349.05 million. During the same quarter in the prior year, the firm posted $0.19 earnings per share. The company’s revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, equities research analysts forecast that Progyny, Inc. will post 1.25 earnings per share for the current year.

Institutional Trading of Progyny

Several institutional investors have recently modified their holdings of PGNY. Toth Financial Advisory Corp raised its position in shares of Progyny by 21.3% during the 3rd quarter. Toth Financial Advisory Corp now owns 2,735 shares of the company’s stock worth $69,000 after purchasing an additional 480 shares during the last quarter. WINTON GROUP Ltd lifted its stake in Progyny by 266.7% in the 2nd quarter. WINTON GROUP Ltd now owns 251,834 shares of the company’s stock valued at $7,260,000 after buying an additional 183,163 shares in the last quarter. Engineers Gate Manager LP lifted its stake in Progyny by 5.6% in the 2nd quarter. Engineers Gate Manager LP now owns 152,757 shares of the company’s stock valued at $4,404,000 after buying an additional 8,156 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Progyny in the 2nd quarter worth about $74,000. Finally, IFP Advisors Inc boosted its holdings in Progyny by 376.0% in the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after buying an additional 1,549 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PGNY. Citigroup reaffirmed an “outperform” rating on shares of Progyny in a report on Tuesday, September 8th. Weiss Ratings raised Progyny from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Barclays cut their price objective on Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 12th. Wall Street Zen raised Progyny from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 19th. Finally, Truist Financial upped their target price on Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Progyny has an average rating of “Moderate Buy” and an average price target of $34.36.

Read Our Latest Stock Report on PGNY

Progyny Company Profile

(Get Free Report)

Progyny, Inc (NASDAQ: PGNY) is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs.

The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.